GALVUS NOVARTIS PDF

Novartis’ Galvus (vildagliptin) is a member of a new class of oral antidiabetic agents known as dipeptidyl peptidase IV inhibitors (DPP-IV) inhibitors or ‘incretin . Galvus Approval Status. FDA Approved: No Brand name: Galvus Generic name: vildagliptin. Previous Name: LAF Company: Novartis Pharmaceuticals. Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral.

Author: Grokora Zulkilar
Country: Puerto Rico
Language: English (Spanish)
Genre: Love
Published (Last): 10 April 2017
Pages: 366
PDF File Size: 3.75 Mb
ePub File Size: 16.47 Mb
ISBN: 229-7-87284-196-5
Downloads: 5486
Price: Free* [*Free Regsitration Required]
Uploader: Babar

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) | European Medicines Agency

Renal hovartis A multiple-dose, open-label trial was conducted to evaluate the pharmacokinetics of the lower therapeutic dose of vildagliptin 50 mg once daily in patients nnovartis varying degrees of chronic renal impairment defined novratis creatinine clearance mild: Vildagliptin launched by Novartis for dual therapy in type 2 diabetes.

Sunitinib The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Vildagliptin. Cortivazol The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Cortivazol.

The risk or severity of hypoglycemia can be increased when Vildagliptin is combined with Guar gum. Clobetasol The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Clobetasol. The risk or severity of angioedema can be increased when Vildagliptin is combined with Saruplase.

The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfanitran. By raising GLP-1 levels the drug also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion.

Sulfadimethoxine The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfadimethoxine. Repaglinide The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Vildagliptin. Icandra should not be used in people who may be hypersensitive allergic to vildagliptin, metformin or any of the other ingredients. Testosterone enanthate Testosterone enanthate may increase the hypoglycemic activities of Vildagliptin.

  BUGIARDINO YAZ PDF

Gastrointestinal symptoms, particularly soft faeces, mucoid faeces, diarrhoea and, at higher doses, faecal blood were observed in dogs. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sitafloxacin.

For more information please take a look at our terms and conditions. Lipoic Acid The risk or severity of hypoglycemia can be increased when Lipoic Acid is combined with Vildagliptin. The name of the medicine was changed to Icandra on 6 February Rescinnamine The risk or severity of angioedema can be increased when Rescinnamine is combined with Vildagliptin. Galvjs Following oral administration in the fasting state, vildagliptin is rapidly absorbed, with peak plasma concentrations observed at 1.

Following oral administration in the fasting state, vildagliptin is rapidly absorbed, with peak plasma concentrations observed at 1. Insulin Aspart Vildagliptin may increase the hypoglycemic activities of Insulin Aspart. At study endpoint 2 yearsthe HbA 1c was similar to baseline values in both treatment groups and the body weight changes and hypoglycaemia differences were maintained.

By clicking Subscribe, I agree to the Drugs. glavus

Galvus 50 mg Tablets

The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfametomidine. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Leuprolide.

Hepatitis reversible upon discontinuation of the medicinal product Abnormal liver function tests reversible upon discontinuation of the medicinal product. Captopril The risk or severity of angioedema can be increased when Captopril is combined with Vildagliptin.

Saruplase The risk or severity of angioedema can be increased when Vildagliptin is combined with Saruplase. Milnacipran The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Vildagliptin. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Setrobuvir. The safety and efficacy of vildagliptin as triple oral therapy in combination with metformin and a thiazolidinedione have not been established.

Pazufloxacin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Pazufloxacin. The risk or severity of hypoglycemia can be increased when Efonidipine is combined with Vildagliptin.

  JASVINDER SANGHERA SHAME PDF

Vildagliptin

The therapeutic efficacy of Vildagliptin can be increased when used in combination with Ertugliflozin. Sulfamethizole The therapeutic efficacy of Falvus can be increased when used in combination with Sulfamethizole. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Cinoxacin.

The therapeutic efficacy of Vildagliptin novartix be increased when used in combination with Furosemide. Insulin Glulisine Vildagliptin may increase the hypoglycemic activities of Insulin Glulisine. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Darunavir. The risk or severity of angioedema can be increased when Vildagliptin is combined with Linagliptin.

The risk or severity of hypoglycemia can be increased when Phenformin is combined with Vildagliptin. Enoxacin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Enoxacin. The risk or severity of hypoglycemia can novwrtis increased when Manidipine is combined with Vildagliptin. More detail is available in the summary of product characteristics. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Buserelin.

Clevidipine The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Vildagliptin. Aminosalicylic Acid Aminosalicylic Acid may increase the hypoglycemic activities of Vildagliptin.

The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Clobetasol. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Celecoxib. Vildagliptin in combination with insulin significantly decreased HbA 1c compared with placebo. The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Vildagliptin.

The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methyclothiazide.